Archives
Cohort study finds racial minorities face more severe COVID-19 outcomes.
18 May, 2021 | 07:44h | UTCRacial minorities face more severe COVID-19 outcomes – CIDRAP
Priorities for COVID-19 research response and preparedness in low-resource settings.
18 May, 2021 | 07:46h | UTCPriorities for COVID-19 research response and preparedness in low-resource settings – The Lancet
Analysis: Where are we with drug treatments for covid-19?
18 May, 2021 | 07:47h | UTCWhere are we with drug treatments for covid-19? – The BMJ
#ACC21 – The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030 – “The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women”.
18 May, 2021 | 07:32h | UTCHomepage: The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030 – The Lancet (free registration required)
Infographic: Women and cardiovascular disease
Video: The Lancet women and cardiovascular disease Commission
News release: Experts call for urgent action to reduce global burden of cardiovascular disease in women by 2030 – The Lancet
Commentary on Twitter (thread – click for more)
Cardiovascular disease is responsible for 35% of deaths in women yearly—yet remains:
❣️Understudied
❣️Under-recognised
❣️Underdiagnosed
❣️UndertreatedNEW @TheLancet Commission outlines 10 recommendations to improve health outcomes for millions of women: https://t.co/DDB97FFunC pic.twitter.com/WjV3aqqLV9
— The Lancet (@TheLancet) May 17, 2021
#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.
18 May, 2021 | 07:34h | UTCAspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial – The Lancet (free registration required)
Commentaries: Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy – HOST-EXAM – American College of Cardiology AND Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM – TCTMD
Commentary on Twitter
The sensational news of the day comes from South Korea. In a timely comparison of single antiplatelet monotherapies, clopidogrel beats aspirin during the chronic maintenance period after PCI, with curves diverging at 9 months. #ACC21https://t.co/Pp49LxcNWf pic.twitter.com/J9Un4QHzgL
— Davide Capodanno (@DFCapodanno) May 16, 2021
WHO study estimates long working hours causing 745.000 deaths a year from heart disease and stroke.
18 May, 2021 | 07:29h | UTCNews Release: Long working hours increasing deaths from heart disease and stroke: WHO, ILO – World Health Organization
Commentary: Long working hours killing 745,000 people a year, study finds – BBC
Commentary on Twitter (thread – click for more)
🆕 WHO & @ilo analysis shows that working 55 hours or more per week impacts #WorkersHealth & increases risk of cardiovascular diseases.
Long working hours led to 745 000 deaths from #stroke & ischemic heart disease in 2016, a 2⃣9⃣% rise ↗️ since 2000.
👉 https://t.co/T3nuPX3nH7 pic.twitter.com/UW5XxbjWqo
— World Health Organization (WHO) (@WHO) May 17, 2021
Opinion | E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth.
18 May, 2021 | 07:28h | UTCE-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth – Think Global Health
Commentary on Twitter (thread – click for more)
📢📢📢 @US_FDA should ban flavors in all nicotine-containing products, not just menthol cigarettes. More than 8 out of 10 current youth e-cigarette users in the U.S. vape non-tobacco flavors.
IHME researchers for @ThinkGlobalHlth 🧵⤵️ https://t.co/d56mDCvTY3
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) May 17, 2021
M-A: Screening test (Hospital Anxiety and Depression Scale – HADS-D) can identify hospitalized patients with depression.
18 May, 2021 | 07:23h | UTCKnowledge translation tool: Using the HADS-D to Screen for Depression
Commentary on Twitter (thread – click for more)
Our @DepressdP IPDMA on HADS-D accuracy, led by Dr. Yin Wu, was published today in @bmj_latest! We pooled data from 101 studies and found that a cutoff of >=7 maximized combined sensitivity and specificity. Read more here: https://t.co/iMmsjoeW7f
— Brooke Levis (@blevis_epi) May 10, 2021
Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.
18 May, 2021 | 07:27h | UTC
Expert consensus on peri-operative myocardial injury screening in noncardiac surgery.
18 May, 2021 | 07:12h | UTCInvited Commentary: Expert consensus on peri-operative myocardial injury screening in noncardiac surgery
RCT: Among patients with esophageal cancer, intrathoracic anastomosis after totally or hybrid minimally invasive esophagectomy resulted in lower anastomotic leakage rates and better outcomes when compared with cervical anastomosis.
18 May, 2021 | 07:21h | UTCIntrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited commentary: Does the Location Matter for the Anastomosis for Minimally Invasive Esophagectomy? (free for a limited period)
Commentary on Twitter
Intrathoracic anastomosis after MIE is associated with a lower anastomotic leakage rate and better outcome for patients with mid to distal esophageal or gastro-esophageal junction cancer: results of the ICAN trial https://t.co/CXv2CeCnuX pic.twitter.com/QCYg4UJeyF
— JAMA Surgery (@JAMASurgery) May 12, 2021
NICE Guideline Update | Headaches in over 12s: diagnosis and management.
18 May, 2021 | 07:14h | UTCHeadaches in over 12s: diagnosis and management – National Institute for Health and Care Excellence
WSES-AAST guidelines: Management of inflammatory bowel disease in the emergency setting.
18 May, 2021 | 07:15h | UTC
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
17 May, 2021 | 08:56h | UTCInvited commentary: Convalescent plasma in patients hospitalised with COVID-19
Commentaries on Twitter
Convalescent plasma:
Yet another example of
Don’t guess, don’t gamble
Randomize… and learn
I’ve heard it said that it was deemed “too difficult” to do a randomised controlled trial. Really? If that’s the case, we must (and can) fix that problem. Pts deserve better. https://t.co/zxIiK5U63v
— Martin Landray (@MartinLandray) May 15, 2021
NEW #COVID19 research—In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Read https://t.co/7Sbe8V9THp. #RECOVERY #RECOVERYtrial pic.twitter.com/D0OLZKxZc4
— The Lancet (@TheLancet) May 16, 2021
AI-based pathology predicts origins for cancers of unknown primary.
18 May, 2021 | 07:11h | UTCAI-based pathology predicts origins for cancers of unknown primary – Nature
Commentary on Twitter
A paper published in Nature presents a deep-learning algorithm for classification of cancers of unknown primary origin. https://t.co/IZQ13XWzJn pic.twitter.com/WjKW3kQz3N
— Nature Portfolio (@NaturePortfolio) May 15, 2021
[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.
17 May, 2021 | 08:53h | UTCCommentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre
Disease surveillance for the COVID-19 era: time for bold changes.
17 May, 2021 | 08:54h | UTCDisease surveillance for the COVID-19 era: time for bold changes – The Lancet
Commentary on Twitter
https://twitter.com/Chikwe_I/status/1393544947970760707
Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions.
17 May, 2021 | 08:51h | UTCCommentaries: Expert reaction to study looking at the public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines – Science Media Centre AND Delaying second Covid vaccine doses can save lives, study finds – The Guardian AND Delaying second COVID vaccine dose may prevent deaths under certain conditions – The BMJ
The pandemic surge at home is threatening an Indian vaccinemaker’s bid to protect the world.
17 May, 2021 | 08:42h | UTC
#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.
17 May, 2021 | 08:49h | UTC
Commentaries on Twitter
DARE-19 trial #ACC21 @ACCinTouch
Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile
🎯 Do not discontinue SGLT2i in 🏥 for #COVID19
Full slideset available in 👇https://t.co/RPi5mpPbbN pic.twitter.com/B9VQdSSAFu
— Enrique Santas (@SantasEnrique) May 16, 2021
DARE-19 findings presented at #ACC21 show #dapagliflozin didn’t significantly ⬇️ risk of organ failure or death or improve recovery in patients hospitalized w/ #COVID19. However, data suggest the SGLT2 inhibitor was well tolerated in acutely ill patients. https://t.co/YjYxbuc952 pic.twitter.com/J4PqwvGpLJ
— American College of Cardiology (@ACCinTouch) May 16, 2021
‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.
17 May, 2021 | 08:45h | UTC‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT
India’s COVID-19 crisis: a call for international action.
17 May, 2021 | 08:43h | UTCIndia’s COVID-19 crisis: a call for international action – The Lancet
Commentary on Twitter (thread – click for more)
The team @IndiaCOVIDSOS and others call for international action for India’s COVID-19 crisis in their Lancet paper.https://t.co/T7RvexuMJP@paimadhu @PrakashLab @KrutikaKuppalli @BhramarBioStat @spkalantri @cspramesh pic.twitter.com/QkuYv2QEb6
— Raj Kumar Manna (@rajphys) May 14, 2021
Setting the record straight: There is no ‘Covid heart’.
17 May, 2021 | 08:47h | UTCSetting the record straight: There is no ‘Covid heart’ – STAT
Commentary on Twitter
Why the issue of Covid-19 induced cardiac problems was massively overblown and why screening low-risk patients with MRI and other fancy tests is neither necessary nor wise. https://t.co/HkJFOJ6oeM
— Raffaele Rasoini (@RasoiniR) May 14, 2021
#ACC21 – Practice Changing RCT: In patients with atrial fibrillation (75% maintained on anticoagulation), left atrial appendage occlusion during cardiac surgery reduces the incidence of stroke and systemic embolism (4.8 vs. 7.0%) in the following years.
17 May, 2021 | 08:33h | UTCLeft Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Simple surgery prevents strokes in heart patients – McMaster University AND Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III – TCTMD
Video: The Left Atrial Appendage Occlusion Study (LAAOS) III
Commentary on Twitter
A visual abstract of the #ACC21 Left Atrial Appendage Occlusion Study III is now available, evaluating surgical #LAAO compared with no occlusion among patients with #AFib undergoing open heart surgery for another indication. https://t.co/3iIhAEuGwk pic.twitter.com/e9Wq6Bp3Zz
— American College of Cardiology (@ACCinTouch) May 15, 2021
#ACC21 – RCT: No significant differences in cardiovascular events or major bleeding between patients receiving 81 mg vs. 325 mg of aspirin daily.
17 May, 2021 | 08:31h | UTCComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE – TCTMD AND Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness – ADAPTABLE – American College of Cardiology
Video: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial